Immix Biopharma Announces 72-Patient NXC-201 Clinical Data At The IMS 20th Annual Meeting, 95% Overall Response Rate In Multiple Myeloma
Portfolio Pulse from Benzinga Newsdesk
Immix Biopharma has announced clinical data for NXC-201 at the IMS 20th Annual Meeting, showing a 95% overall response rate in relapsed/refractory multiple myeloma patients not previously treated with BCMA-targeted therapy. The company plans to submit a BLA for FDA approval in multiple myeloma once 100 patients are treated with NXC-201.
October 02, 2023 | 12:07 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Immix Biopharma's NXC-201 shows promising results in clinical trials, which could lead to FDA approval and potential market success.
The positive clinical trial results for Immix Biopharma's NXC-201 indicate a high likelihood of FDA approval, which would allow the company to market the drug for multiple myeloma treatment. This could significantly boost the company's revenues and positively impact its stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100